IL323244A - נוגדנים כנגד cd161 ושיטות השימוש בהם - Google Patents
נוגדנים כנגד cd161 ושיטות השימוש בהםInfo
- Publication number
- IL323244A IL323244A IL323244A IL32324425A IL323244A IL 323244 A IL323244 A IL 323244A IL 323244 A IL323244 A IL 323244A IL 32324425 A IL32324425 A IL 32324425A IL 323244 A IL323244 A IL 323244A
- Authority
- IL
- Israel
- Prior art keywords
- antibodies
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363500122P | 2023-05-04 | 2023-05-04 | |
| PCT/US2024/028001 WO2024229461A2 (en) | 2023-05-04 | 2024-05-06 | Anti-cd161 antibodies and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL323244A true IL323244A (he) | 2025-11-01 |
Family
ID=91248035
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL323244A IL323244A (he) | 2023-05-04 | 2025-09-08 | נוגדנים כנגד cd161 ושיטות השימוש בהם |
Country Status (5)
| Country | Link |
|---|---|
| CN (1) | CN121079326A (he) |
| AU (1) | AU2024265613A1 (he) |
| IL (1) | IL323244A (he) |
| TW (1) | TW202509069A (he) |
| WO (1) | WO2024229461A2 (he) |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| DE3856559T2 (de) | 1987-05-21 | 2004-04-29 | Micromet Ag | Multifunktionelle Proteine mit vorbestimmter Zielsetzung |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| WO1991010741A1 (en) | 1990-01-12 | 1991-07-25 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| DE69233745D1 (de) | 1991-12-02 | 2008-10-23 | Cambridge Antibody Tech | Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken |
| CN101940189A (zh) | 2000-11-30 | 2011-01-12 | 米德列斯公司 | 用于生产人类抗体的转基因转染色体啮齿动物 |
| WO2004004771A1 (ja) | 2002-07-03 | 2004-01-15 | Ono Pharmaceutical Co., Ltd. | 免疫賦活組成物 |
| JP4361545B2 (ja) | 2005-05-09 | 2009-11-11 | 小野薬品工業株式会社 | ＰｒｏｇｒａｍｍｅｄＤｅａｔｈ１（ＰＤ−１）に対するヒトモノクローナル抗体および抗ＰＤ−１抗体単独または他の免疫療法と併用した癌治療方法 |
| HRP20151102T1 (xx) | 2005-07-01 | 2015-11-20 | E. R. Squibb & Sons, L.L.C. | Humana monoklonska antitijela za ligand programirane smrti 1 (pd-l1) |
| NZ582150A (en) | 2007-06-18 | 2012-08-31 | Msd Oss Bv | Antibodies to human programmed death receptor pd-1 |
| JP2012510429A (ja) | 2008-08-25 | 2012-05-10 | アンプリミューン、インコーポレーテッド | Ｐｄ−１アンタゴニストおよびその使用方法 |
| KR20250091300A (ko) | 2008-12-09 | 2025-06-20 | 제넨테크, 인크. | 항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도 |
| JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害 |
| KR102266097B1 (ko) | 2010-06-22 | 2021-06-18 | 리제너론 파아마슈티컬스, 인크. | 사람 람다 가변 영역 및 마우스 불변 영역을 갖는 경쇄를 발현하는 마우스 |
| SMT202000561T1 (it) | 2011-11-28 | 2021-01-05 | Merck Patent Gmbh | Anticorpi anti-pd-l1 e usi relativi |
| SG10201700698WA (en) | 2012-05-15 | 2017-02-27 | Bristol Myers Squibb Co | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| US10239942B2 (en) | 2014-12-22 | 2019-03-26 | Pd-1 Acquisition Group, Llc | Anti-PD-1 antibodies |
| EP3641812A1 (en) | 2017-06-22 | 2020-04-29 | Novartis AG | Antibody molecules to cd73 and uses thereof |
| US12018080B2 (en) * | 2017-11-13 | 2024-06-25 | The Broad Institute, Inc. | Methods and compositions for treating cancer by targeting the CLEC2D-KLRB1 pathway |
| AU2019235842B2 (en) | 2018-03-14 | 2022-02-03 | Surface Oncology, Inc. | Antibodies that bind CD39 and uses thereof |
| US11459389B2 (en) * | 2019-10-24 | 2022-10-04 | Massachusetts Institute Of Technology | Monoclonal antibodies that bind human CD161 |
| KR20240099138A (ko) * | 2021-08-23 | 2024-06-28 | 이뮤니타스 테라퓨틱스, 인크. | 항-cd161 항체 및 그의 용도 |
-
2024
- 2024-05-06 AU AU2024265613A patent/AU2024265613A1/en active Pending
- 2024-05-06 CN CN202480026299.XA patent/CN121079326A/zh active Pending
- 2024-05-06 WO PCT/US2024/028001 patent/WO2024229461A2/en active Pending
- 2024-05-06 TW TW113116726A patent/TW202509069A/zh unknown
-
2025
- 2025-09-08 IL IL323244A patent/IL323244A/he unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024229461A2 (en) | 2024-11-07 |
| WO2024229461A3 (en) | 2024-12-26 |
| TW202509069A (zh) | 2025-03-01 |
| CN121079326A (zh) | 2025-12-05 |
| AU2024265613A1 (en) | 2025-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB202019709D0 (en) | Anti-Coronavirus antibodies and methods of use | |
| CA3252754A1 (en) | Anti-TL1A antibodies and their methods of use | |
| SI4200018T1 (sl) | Protitelesa proti-PAR-2 in postopki njihove uporabe | |
| IL316065A (he) | נוגדנים אנטי- cd28ושיטות לשימוש בהם | |
| CA3266793A1 (en) | ANTI-B7H3 ANTIBODIES AND METHODS OF USE | |
| IL317690A (he) | נוגדנים אנטי- gpnmbושיטות לשימוש בהם | |
| CA3263543A1 (en) | CCR8 ANTIBODIES AND METHODS OF USE | |
| IL315845A (he) | נוגדנים אנטי-דקטין-1 ושיטות לשימוש בהם | |
| IL323285A (he) | נוגדנים נגד פוספוכולין ושיטות לשימוש בהם | |
| IL308260A (he) | נוגדנים נגד טיגיט ודרכי השימוש בהם | |
| CA3266931A1 (en) | ANTI-NAPI2B ANTIBODIES AND METHODS OF USE | |
| IL319590A (he) | נוגדנים רב-ספציפיים ושיטות לשימוש בהם | |
| CA3261520A1 (en) | ANTIBODIES, THEIR MANUFACTURING PROCESSES AND METHODS OF USE | |
| IL323599A (he) | נוגדנים נגד il-25 ושיטות לשימוש בהם | |
| IL323244A (he) | נוגדנים כנגד cd161 ושיטות השימוש בהם | |
| CA3263793A1 (en) | ANTI-IL27R ANTIBODIES AND THEIR METHODS OF USE | |
| IL316700A (he) | נוגדני anti-bmp9 ושיטות השימוש בהם | |
| IL316894A (he) | נוגדני anti-tnfr2 ושיטות השימוש בהם | |
| IL323120A (he) | נוגדנים כנגד b7h3 ושיטות שימוש | |
| IL321679A (he) | נוגדני אנטי-ror2 ושיטות לשימוש | |
| CA3275232A1 (en) | Anti-PDL1 antibodies and methods of use | |
| IL310551A (he) | נוגדנים חד-שבטיים ספציפיים ל-osmr ושיטות השימוש בהם | |
| IL311003A (he) | נוגדנים אנטי-2her ושיטות שימוש בהם | |
| HK40121486A (zh) | 抗il-25抗体及其使用方法 | |
| HK40118098A (zh) | 抗gpnmb抗体及其使用方法 |